This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6
billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1
According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.
While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. billion in 2029, while Calquence is expected to make $5.31 billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in the same year. billion in the same year.
Their report ascertained that growth between 2019-2024 resulted from factors such as quality control demands, cost efficiency, rapid analysis, market competition, healthcare innovations. billion in 2029 at a compound annual growth rate (CAGR) of 7.9 It will grow to $31.77
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
billion by 2029. The potential increase in industry competition could also spell trouble for some. However, current orthopedic medical device trends all point towards the increasing use of such systems. In fact, the market size for orthopedic surgical robots will reach roughly $24.2
million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Sanofi and Regeneron’s market capitalisation grew by 12.4%
Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two hours of patient observation after administration.
billion by 2029. The potential increase in industry competition could also spell trouble for some. However, current orthopedic medical device trends all point towards the increasing use of such systems. In fact, the market size for orthopedic surgical robots will reach roughly $24.2
through 2029. Competitive pressure will drive companies to invest in AI tools for sales. Making a prospect wait hours for a response will become a competitive disadvantage. Presenting an Offer In a competitive sales environment, a sales team may have 30 minutes on a Zoom call to review an offer.
Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. The post Enhancing competitiveness of European life sciences appeared first on European Pharmaceutical Review.
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
Nathalie Moll, Director General, the European Federation of Pharmaceutical Industries and Associations (EFPIA), has commended inclusion of a “dedicated life sciences strategy” in the Political Guidelines for the Next European Commission 2024-2029. As such, she noted that the initial priority will be “prosperity and competitiveness.”
However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products.
billion in 2029. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. The condition gradually worsens and can result in liver failure.
billion in the US alone by 2029. Craft Your Unique Value Proposition Why should prospects buy from your company , not the competition? There’s never been a better time to be in telecom sales. The industry is expected to grow to 530.61 More interest in your telecom services, shorter sales cycles, and ultimately, more sales.
billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.31% over the next five years[ source ]. Soft skills like empathy and adaptability allow reps to stand out in a competitive market. NOTE : The pharmaceutical industry in Malaysia has been experiencing steady growth. billion in revenue, with expectations to reach US$2.1
As California Attorney General from 2011 to 2017, Harris was a forceful opponent of healthcare industry consolidation, both vertical and horizontal, believing that mergers of hospitals, physician groups and insurers would damage competition and raise prices for care.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content